• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

开发和评估一种基于羊抗体的平台,用于治疗艰难梭菌感染。

Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection.

机构信息

Health Protection Agency, Porton Down, Salisbury, Wilts, United Kingdom.

出版信息

Infect Immun. 2012 Feb;80(2):875-82. doi: 10.1128/IAI.05684-11. Epub 2011 Dec 5.

DOI:10.1128/IAI.05684-11
PMID:22144483
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3264293/
Abstract

Treatment of Clostridium difficile is a major problem as a hospital-associated infection which can cause severe, recurrent diarrhea. The currently available antibiotics are not effective in all cases and alternative treatments are required. In the present study, an ovine antibody-based platform for passive immunotherapy of C. difficile infection is described. Antibodies with high toxin-neutralizing titers were generated against C. difficile toxins A and B and were shown to neutralize three sequence variants of these toxins (toxinotypes) which are prevalent in human C. difficile infection. Passive immunization of hamsters with a mixture of toxin A and B antibodies protected them from a challenge with C. difficile spores in a dose-dependent manner. Antibodies to both toxins A and B were required for protection. The administration of toxin A and B antibodies up to 24 h postchallenge was found to reduce significantly the onset of C. difficile infection compared to nonimmunized controls. Protection from infection was also demonstrated with key disease isolates (ribotypes 027 and 078), which are members of the hypervirulent C. difficile clade. The ribotype 027 and 078 strains also have the capacity to produce an active binary toxin and these data suggest that neutralization of this toxin is unnecessary for the management of infection induced by these strains. In summary, the data suggest that ovine toxin A and B antibodies may be effective in the treatment of C. difficile infection; their potential use for the management of severe, fulminant cases is discussed.

摘要

艰难梭菌感染是一种严重的医院相关性感染,可导致严重、反复的腹泻,其治疗是一个主要问题。目前可用的抗生素并非对所有病例均有效,需要替代疗法。本研究描述了一种基于羊抗体的艰难梭菌感染被动免疫治疗平台。针对艰难梭菌毒素 A 和 B 产生了具有高毒素中和效价的抗体,并证明它们能中和在人类艰难梭菌感染中流行的三种毒素序列变体(毒素型)。用毒素 A 和 B 抗体混合物对仓鼠进行被动免疫,可使其在一定剂量范围内免受艰难梭菌孢子的挑战。保护作用需要两种毒素的抗体。与未免疫对照相比,在挑战后 24 小时内给予毒素 A 和 B 抗体可显著减少艰难梭菌感染的发病。用关键疾病分离株(ribotype 027 和 078)也证明了这种保护作用,这些分离株属于高毒力艰难梭菌 clade。ribotype 027 和 078 菌株也有产生活性二元毒素的能力,这些数据表明,中和这种毒素对于管理这些菌株引起的感染是不必要的。总之,这些数据表明,羊毒素 A 和 B 抗体可能对治疗艰难梭菌感染有效;讨论了其在治疗严重、暴发性病例中的潜在用途。

相似文献

1
Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection.开发和评估一种基于羊抗体的平台,用于治疗艰难梭菌感染。
Infect Immun. 2012 Feb;80(2):875-82. doi: 10.1128/IAI.05684-11. Epub 2011 Dec 5.
2
Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B.芽孢杆菌表达毒素 A 肽重复的免疫接种可预防产生毒素 A 和 B 的艰难梭菌菌株的感染。
Infect Immun. 2011 Jun;79(6):2295-302. doi: 10.1128/IAI.00130-11. Epub 2011 Apr 11.
3
Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.两组分艰难梭菌类毒素疫苗诱导的系统抗体应答可预防仓鼠艰难梭菌相关性疾病。
J Med Microbiol. 2013 Sep;62(Pt 9):1394-1404. doi: 10.1099/jmm.0.056796-0. Epub 2013 Mar 21.
4
A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.一种新型多价、单域抗体靶向 TcdA 和 TcdB,可预防小鼠爆发性艰难梭菌感染。
J Infect Dis. 2014 Sep 15;210(6):964-72. doi: 10.1093/infdis/jiu196. Epub 2014 Mar 27.
5
A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.嵌合毒素疫苗可预防原发性和复发性艰难梭菌感染。
Infect Immun. 2012 Aug;80(8):2678-88. doi: 10.1128/IAI.00215-12. Epub 2012 May 21.
6
Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response.基于艰难梭菌毒素 A 和 B 的重组抗原,可引发强烈的毒素中和免疫应答。
Vaccine. 2014 Feb 3;32(6):700-5. doi: 10.1016/j.vaccine.2013.11.099. Epub 2013 Dec 14.
7
Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A.通过使用抗艰难梭菌毒素A单克隆抗体对悉生小鼠实验性假膜性结肠炎的保护作用。
Infect Immun. 1991 Mar;59(3):1192-5. doi: 10.1128/iai.59.3.1192-1195.1991.
8
Equine hyperimmune serum protects mice against Clostridium difficile spore challenge.马超免疫血清可保护小鼠免受艰难梭菌孢子攻击。
J Vet Sci. 2014;15(2):249-58. doi: 10.4142/jvs.2014.15.2.249. Epub 2013 Oct 18.
9
Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.新型艰难梭菌抗毒素(TcdA和TcdB)人源化单克隆抗体在体外对多种临床菌株具有中和作用,并在仓鼠孢子攻击模型中展现出体内效力。
PLoS One. 2016 Jun 23;11(6):e0157970. doi: 10.1371/journal.pone.0157970. eCollection 2016.
10
The roles of toxin A and toxin B in Clostridium difficile infection: insights from the gnotobiotic piglet model.艰难梭菌感染中毒素 A 和毒素 B 的作用:无菌仔猪模型的研究进展。
Gut Microbes. 2014 Jan-Feb;5(1):53-7. doi: 10.4161/gmic.26855. Epub 2013 Oct 31.

引用本文的文献

1
Large Clostridial Toxins: A Brief Review and Insights into Antigen Design for Veterinary Vaccine Development.大型梭菌毒素:简要综述及兽用疫苗开发抗原设计见解
Mol Biotechnol. 2024 Oct 29. doi: 10.1007/s12033-024-01303-6.
2
Immunization Strategies Against Clostridioides difficile.针对艰难梭菌的免疫策略。
Adv Exp Med Biol. 2024;1435:117-150. doi: 10.1007/978-3-031-42108-2_7.
3
Application of recombinant antibodies for treatment of infection: Current status and future perspective.重组抗体在 感染治疗中的应用:现状与展望。
Front Immunol. 2022 Aug 23;13:972930. doi: 10.3389/fimmu.2022.972930. eCollection 2022.
4
A Novel, Orally Delivered Antibody Therapy and Its Potential to Prevent Infection in Pre-clinical Models.一种新型口服抗体疗法及其在临床前模型中预防感染的潜力。
Front Microbiol. 2020 Sep 22;11:578903. doi: 10.3389/fmicb.2020.578903. eCollection 2020.
5
Recent advances in the treatment of using biotherapeutic agents.使用生物治疗药物进行治疗的最新进展。 (原句“Recent advances in the treatment of using biotherapeutic agents.”表述不完整,推测完整句子可能是“Recent advances in the treatment of [某种疾病等] using biotherapeutic agents.” 这里按现有内容翻译)
Infect Drug Resist. 2019 Jun 10;12:1597-1615. doi: 10.2147/IDR.S207572. eCollection 2019.
6
Clostridium difficile Toxoid Vaccine Candidate Confers Broad Protection against a Range of Prevalent Circulating Strains in a Nonclinical Setting.艰难梭菌毒素疫苗候选物在非临床环境中针对广泛流行的循环株提供广泛保护。
Infect Immun. 2018 May 22;86(6). doi: 10.1128/IAI.00742-17. Print 2018 Jun.
7
Functional significance of active site residues in the enzymatic component of the binary toxin.二元毒素酶组分中活性位点残基的功能意义
Biochem Biophys Rep. 2016 Aug 11;8:55-61. doi: 10.1016/j.bbrep.2016.08.011. eCollection 2016 Dec.
8
A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.艰难梭菌感染的实验性和非标签疗法综述
Infect Dis Ther. 2017 Mar;6(1):1-35. doi: 10.1007/s40121-016-0140-z. Epub 2016 Dec 1.
9
An update on antibody-based immunotherapies for Clostridium difficile infection.艰难梭菌感染基于抗体的免疫疗法的最新进展。
Clin Exp Gastroenterol. 2016 Aug 1;9:209-24. doi: 10.2147/CEG.S84017. eCollection 2016.
10
Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection.表达一种多特异性、单结构域抗体以中和艰难梭菌毒素A(TcdA)和毒素B(TcdB)的静脉注射腺病毒可保护小鼠免受艰难梭菌感染。
Pathog Dis. 2016 Oct;74(7). doi: 10.1093/femspd/ftw078. Epub 2016 Aug 7.

本文引用的文献

1
Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain.针对细胞受体结合域的单域抗体中和艰难梭菌毒素 A。
J Biol Chem. 2011 Mar 18;286(11):8961-76. doi: 10.1074/jbc.M110.198754. Epub 2011 Jan 7.
2
Clostridium difficile infection: epidemiology, risk factors and management.艰难梭菌感染:流行病学、危险因素和管理。
Nat Rev Gastroenterol Hepatol. 2011 Jan;8(1):17-26. doi: 10.1038/nrgastro.2010.190. Epub 2010 Nov 30.
3
Treatment of chronically digoxin-poisoned patients with a newer digoxin immune fab--a retrospective study.采用新型地高辛免疫Fab片段治疗慢性地高辛中毒患者——一项回顾性研究
J Am Osteopath Assoc. 2010 Oct;110(10):587-92.
4
Management of Clostridium difficile infection: thinking inside and outside the box.艰难梭菌感染的管理:跳出固有思维。
Clin Infect Dis. 2010 Dec 1;51(11):1306-13. doi: 10.1086/657116. Epub 2010 Oct 27.
5
The role of toxin A and toxin B in Clostridium difficile infection.艰难梭菌感染中毒素 A 和毒素 B 的作用。
Nature. 2010 Oct 7;467(7316):711-3. doi: 10.1038/nature09397. Epub 2010 Sep 15.
6
Clostridium difficile toxin A decreases acetylation of tubulin, leading to microtubule depolymerization through activation of histone deacetylase 6, and this mediates acute inflammation.艰难梭菌毒素 A 降低微管蛋白的乙酰化,通过激活组蛋白去乙酰化酶 6 导致微管解聚,从而介导急性炎症。
J Biol Chem. 2010 Oct 22;285(43):32888-32896. doi: 10.1074/jbc.M110.162743. Epub 2010 Aug 9.
7
The emergence of 'hypervirulence' in Clostridium difficile.艰难梭菌“超级毒力”的出现。
Int J Med Microbiol. 2010 Aug;300(6):387-95. doi: 10.1016/j.ijmm.2010.04.008. Epub 2010 May 23.
8
Treatment with monoclonal antibodies against Clostridium difficile toxins.针对艰难梭菌毒素的单克隆抗体治疗。
N Engl J Med. 2010 Jan 21;362(3):197-205. doi: 10.1056/NEJMoa0907635.
9
Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria.艰难梭菌毒素CDT诱导基于微管的突起形成并增加细菌的黏附。
PLoS Pathog. 2009 Oct;5(10):e1000626. doi: 10.1371/journal.ppat.1000626. Epub 2009 Oct 16.
10
Cwp84, a surface-associated cysteine protease, plays a role in the maturation of the surface layer of Clostridium difficile.Cwp84,一种表面相关的半胱氨酸蛋白酶,在艰难梭菌表面层的成熟过程中发挥作用。
J Biol Chem. 2009 Dec 11;284(50):34666-73. doi: 10.1074/jbc.M109.051177. Epub 2009 Oct 6.